{"id":"NCT01072149","sponsor":"GlaxoSmithKline","briefTitle":"A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo","officialTitle":"A Three-way Incomplete Block Crossover Study to Investigate the 24-hour Pulmonary Function of Three Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder vs. Placebo, in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-01-01","primaryCompletion":"2010-07-01","completion":"2010-07-01","firstPosted":"2010-02-19","resultsPosted":"2013-12-25","lastUpdate":"2017-11-09"},"enrollment":54,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Pulmonary Disease, Chronic Obstructive"],"interventions":[{"type":"DRUG","name":"Fluticasone Furoate (FF)/GW642444 Inhalation Powder","otherNames":[]},{"type":"DEVICE","name":"placebo","otherNames":[]}],"arms":[{"label":"50mcg Fluticasone Furoate (FF)/25mcg GW642444","type":"EXPERIMENTAL"},{"label":"100mcg Fluticasone Furoate (FF)/25mcg GW642444","type":"EXPERIMENTAL"},{"label":"200mcg Fluticasone Furoate (FF)/25mcg GW642444","type":"EXPERIMENTAL"},{"label":"placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The Purpose of this study is to evaluate the 24-hour spirometry effect Forced Expiratory Volume in One second (FEV1) of 3 doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the end of a 28-day treatment period in subjects with Chronic Obstructive Pulmonary Disease (COPD) compared with placebo. Other objectives are to assess additional efficacy, plus the safety, pharmcodynamics and tolerability of concurrent treatment with Fluticasone Furoate (FF) plus GW642444 when administered at three dose levels for 28 days in subjects with COPD and to assess the steady-state pharmacokinetic profile of Fluticasone Furoatee (FF) and GW642444 at the end of each treatment period.","primaryOutcome":{"measure":"Time-adjusted Area Under the Curve (AUC) (i.e., Weighted Mean) for 24-hour Serial Forced Expiratory Volume in One Second (FEV1) at the End of Each 28-day Treatment Period","timeFrame":"Pre-dose and the end of each 28-day treatment period (up to 19 weeks)","effectByArm":[{"arm":"Placebo","deltaMin":1.297,"sd":0.024},{"arm":"FF/VI 50/25 µg","deltaMin":1.53,"sd":0.0276},{"arm":"FF/VI 100/25 µg","deltaMin":1.517,"sd":0.0282},{"arm":"FF/VI 200/25 µg","deltaMin":1.533,"sd":0.0282}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG002","p":"<0.001"},{"comp":"OG000 vs OG003","p":"<0.001"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":19,"exclusionCount":26},"locations":{"siteCount":8,"countries":["United States"]},"refs":{"pmids":["22789766"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":51},"commonTop":["Cellulitis","Rhinitis","Sinusitis","Upper respiratory tract infection","Urinary tract infection"]}}